Biological activities and binding properties of 23,23-difluoro-25-hydroxyvitamin D3 and its 1 alpha-hydroxy derivative.
23,23-Difluoro-25-hydroxyvitamin D3 is 5-10 times less active than 25-hydroxyvitamin D3 in stimulating intestinal calcium transport, bone calcium mobilization, increasing serum phosphorus, mineralization of rachitic bone, and binding to the plasma transport protein in rats. It is converted to 23,23-difluoro-1 alpha, 25-dihydroxyvitamin D3 by chick renal 25-hydroxyvitamin D-1-hydroxylase. This compound is one-seventh as active as 1,25-dihydroxyvitamin D3 in binding to the chick intestinal receptor for 1,25-dihydroxyvitamin D3. Thus, fluoro substitution on carbon-23 of vitamin D has an unexpected and unexplained suppressive action on plasma binding and biological activity. However, since this substitution does not block the biological response of 25-hydroxyvitamin D3, these results provide additional evidence that 23-hydroxylation of vitamin D is not involved in biological function.
D000818:Animals; D001846:Bone Development / Q000187:drug effects; D002112:Calcifediol / Q000031:analogs & derivatives* / Q000494:pharmacology; D002117:Calcitriol / Q000031:analogs & derivatives* / Q000494:pharmacology; D002118:Calcium / Q000097:blood / Q000378:metabolism; D002135:Calcium-Binding Proteins / Q000378:metabolism; D002645:Chickens; D003600:Cytosol / Q000378:metabolism; D007408:Intestinal Absorption / Q000187:drug effects; D008297:Male; D010758:Phosphorus / Q000097:blood; D051381:Rats
D002135:Calcium-Binding Proteins; D010758:Phosphorus; C045955:23,23-difluoro-25-hydroxyvitamin D3; C045956:1-25-dihydroxy-23,23-difluorovitamin D3; D002117:Calcitriol; D002112:Calcifediol; D002118:Calcium